CD20-targeted therapy: the next generation of antibodies.
Article Details
- CitationCopy to clipboard
van Meerten T, Hagenbeek A
CD20-targeted therapy: the next generation of antibodies.
Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007.
- PubMed ID
- 20350667 [ View in PubMed]
- Abstract
Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody (MoAb) rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse with the original disease. A better understanding of the mechanism of rituximab resistance has led to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 MoAbs and explains new strategies to overcome resistance.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Rituximab B-lymphocyte antigen CD20 Protein Humans YesAntibodyRegulatorDetails